Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease

Area of Science:

• Hematology
• Transfusion Medicine
• Gene Therapy

Background:

• Sickle cell disease (SCD) management relies heavily on red blood cell (RBC) transfusions to address acute and chronic complications.
• Alloimmunization and iron overload are significant challenges in chronic RBC transfusion therapy for SCD.
• Hematopoietic stem cell transplant (HSCT) and emerging autologous stem cell gene therapy represent potential curative strategies for SCD.

Purpose of the Study:

• To review the indications and complications associated with RBC transfusions in sickle cell disease.
• To outline strategies for managing transfusion support during HSCT.
• To discuss methods for HSC mobilization and collection for autologous HSCT with gene therapy.

Main Methods:

• Review of current literature on RBC transfusion practices in SCD.
• Analysis of complications, including alloimmunization and iron overload, and their management.
• Examination of HSCT protocols and HSC collection techniques for gene therapy.

Main Results:

• Prophylactic Rh and K antigen matching and iron chelation are key to minimizing transfusion complications.
• Matched sibling donor HSCT is a curative treatment option for selected SCD patients.
• Autologous HSC-based gene therapy shows promise, emphasizing the need for efficient HSC mobilization and collection.

Conclusions:

• Optimized RBC transfusion strategies are essential for managing SCD, alongside preventative measures for alloimmunization and iron overload.
• HSCT and autologous gene therapy are advancing as curative options for SCD.
• Successful gene therapy hinges on the effective mobilization and collection of hematopoietic stem cells.